Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.

Objective: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course.

Materials And Methods: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies.

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

Objectives: To investigate the efficacy and safety of fingolimod (FTY) 0.5 mg administered every other day (FTY-EOD) compared to every day (FTY-ED) in multiple sclerosis patients.

Methods: Multicentre retrospective observational study.